Drugs / Sandostatin LAR Depot
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT01121939 | May 2010 → Feb 2015 | neuroendocrine carcinoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00094146 | Jan → Dec 2002 | endocrine pancreas disorder, obesity disorder | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00001860 | Aug 1999 → Jul 2002 | acromegaly, pituitary tumor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01789281 Background | May 2013 → Aug 2020 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sandostatin LAR Depot | “Subjects were allowed to continue combination therapy with Sandostatin LAR® Depot if they were receiving this combination therapy on the parent protocol.” NCT01789281 ↗ |
| Known as | Sandostatin LAR (Registered Trademark) Depot | “The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients...” NCT00001860 ↗ |
| Route | Intramuscular | “30 mg will be given every 28 days by IM injection” NCT01121939 ↗ |